Skip to main content
SpringerLink
Log in

Kinaseinhibitoren in der Onkologie

Was ist neu?

Kinase inhibitors in oncology

What is new?

  • Arzneimitteltherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Kinaseinhibitoren zählen mittlerweile zu den wichtigsten Medikamenten der gerichteten Therapie und finden insbesondere in der Krebstherapie unterschiedlicher Tumorentitäten Einsatz. Da viele Kinaseinhibitoren verschiedene Tyrosinkinasen zwar effizient, jedoch nicht spezifisch hemmen, zeichnen sie sich häufig durch ihren vielseitigen Einsatz in den verschiedensten Entitäten und Erkrankungen aus. Der vielfältige Einsatz dieser Medikamentengruppe, aber auch die Herausforderungen ihres Nebenwirkungsprofils machen Kinaseinhibitoren weiterhin zum Gegenstand zahlreicher klinischer Studien. Der vorliegende Beitrag bietet einen Überblick über einige aktuelle Neuzulassungen auf dem Feld der Kinaseinhibitoren und zeigt ihre Bedeutung für die onkologische Therapie auf.

Abstract

Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in a wide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abou-Alfa GK, Meyer T, Ann-Lii Cheng, El-Khoueiry AB, Rimassa LMD, Baek-Yeol Ryoo, Irfan Cicin, Merle P, YenHsun Chen, Joong-Won Park, Blanc J‑F, Bolondi L et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379:54–63

    Article  CAS  Google Scholar 

  2. Altman J et al ASCO 2017. Abstract #7003, 2017

  3. Altman J et al EHA 2017. Abstract #S110, 2017

  4. Brümmendorf TH, Cortes JE, de Souza CA et al (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168:69–81

    Article  Google Scholar 

  5. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W et al (2013) Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42

    Article  CAS  Google Scholar 

  6. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35(6):591–597

    Article  CAS  Google Scholar 

  7. Cortes JE, Kim DW, Pinilla-Ibarz J et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5‑year results of the phase 2 PACE trial. Blood. https://doi.org/10.1182/blood-2016-09-739086

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Constantine TMB, Orsucci L, Palomba ML, Matous JV et al (2018) Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med 378:2399–2410

    Article  CAS  Google Scholar 

  9. Druker BJ (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417

    Article  CAS  Google Scholar 

  10. Gorre ME (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876–880

    Article  CAS  Google Scholar 

  11. Soria J‑C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Ki Hyeong L, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

    Article  CAS  Google Scholar 

  12. Klaeger S (2017) The target landscape of clinical kinase drugs. Science 358(6367):eaan4368

    Article  Google Scholar 

  13. Levis MJ et al ASH 2012, S Abstract #643, 2012

  14. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243–2250

    Article  CAS  Google Scholar 

  15. O’Brien SG (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004

    Article  Google Scholar 

  16. Oran B et al EHA 2017. Abstract #S792, 2017

  17. Peters S, Camidge RD, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829–838

    Article  CAS  Google Scholar 

  18. Röllig C, Serve H, Hüttmann A et al (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 16:1691–1699

    Article  Google Scholar 

  19. Röllig C, Serve H, Hüttmann A et al (2017) The addition of Sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized-controlled Soraml trial. Annual Meeting of the American Society for Hematology (ASH) 2017, Abstract.621. (https://ash.confex.com/ash/2017/webprogram/Paper106668.html)

    Google Scholar 

  20. Stone RM, Mandrekar S, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454–464

    Article  CAS  Google Scholar 

  21. Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani R, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson PW, Spurgeon SE, Zhang L, Baher L, Cheng M, Beaupre DM, Blum KA (2014) Single-agent Ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, Multicenter, open-label phase 2 study. Blood 124:4453

    Google Scholar 

  22. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-ABL1 for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345–356. https://doi.org/10.1038/nrc2126

    Article  CAS  PubMed  Google Scholar 

  23. Zhang W, Konopleva M, Shi YX et al (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100:184–198

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III für Hämatologie und internistische Onkologie, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, München, Deutschland

    K. Riedmann,  F. Bassermann &  P. J. Jost

  2. Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnerstandort München des Deutschen Krebsforschungszentrums Heidelberg (DKFZ), München, Deutschland

    F. Bassermann &  P. J. Jost

Authors
  1. K. Riedmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bassermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. J. Jost
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Bassermann.

Ethics declarations

Interessenkonflikt

P.J. Jost: Honorare oder Forschungsförderung von Pfizer, Novartis, BMS, AbbVie, Böhringer Ingelheim, Roche. F. Bassermann: Forschungsförderung von Celgene und Beratertätigkeit für BMS, Janssen, Amgen. K. Riedmann gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Wehling, Mannheim

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riedmann, K., Bassermann, F. & Jost, P.J. Kinaseinhibitoren in der Onkologie. Internist 60, 540–544 (2019). https://doi.org/10.1007/s00108-019-0577-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-019-0577-8

Schlüsselwörter

Keywords

Search

Navigation